SELLAS Life Sciences Group, Inc.
13.95USD
-0.0100 (-0.07%)
Consensus EPS on the street’s adjusted basis, not the filed GAAP figure — which is why the actuals here can differ from the income statement.
| Period | Consensus EPS | 90 days ago | Revisions up (30d) | Revisions down (30d) |
|---|---|---|---|---|
| Current quarter | $-0.05▲ | $-0.06 | 0 | 0 |
| Next quarter | $-0.05▲ | $-0.06 | 0 | 0 |
| Current year | $-0.2▲ | $-0.21 | 0 | 0 |
| Next year | $-0.1▲ | $-0.15 | 1 | 0 |
Beat in 2 of the last 3
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| 2026-06-30 | $-0.05 | $-0.05 | -0.01 (-11.1%) |
| 2025-12-31 | $-0.06 | $-0.05 | +0.01 (+21.0%) |
| 2025-09-30 | $-0.08 | $-0.06 | +0.02 (+21.7%) |
13 ratings from 5 firms
Ratings are attributed to the research firm, not to individual analysts. See every ticker.
| Firm | Action | Rating | Price Target | Date |
|---|---|---|---|---|
| Maxim Group | Maintained | Buy | $7 $10 | Mar 12, 2026 |
| Maxim Group | Maintained | Buy | $4 $7 | Jul 16, 2025 |
| Cantor Fitzgerald | Reiterated | Overweight | $3 | Nov 22, 2023 |
| Cantor Fitzgerald | Reiterated | Overweight | $3 | Sep 7, 2023 |
| Alliance Global Partners | Maintained | Buy | $14 $8 | Nov 15, 2022 |
| Cantor Fitzgerald | Maintained | Overweight | $10 $6 | Jun 28, 2022 |
| Cantor Fitzgerald | Initiated | Overweight | $18 | Jul 21, 2021 |
| Maxim Group | Upgraded from Hold | Buy | $12 | Nov 15, 2019 |
| Alliance Global Partners | Initiated | Buy | $4.5 | Apr 8, 2019 |
| Oppenheimer | Initiated | Outperform | $13 | Nov 1, 2018 |
| Maxim Group | Maintained | Buy | $13 $5 | Jul 20, 2018 |
| HC Wainwright & Co. | Initiated | Buy | $11 | Apr 2, 2018 |
| Maxim Group | Upgraded from Hold | Buy | — | Mar 19, 2018 |
20 filings from 8 insiders · 0 buy / 0 sell over 6m
Officers and directors of SLS, from the last two years of filings. Grants, gifts and option exercises are shown but not colour-coded — they are compensation, not a view on the price.
| Insider | Action | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| STERGIOU ANGELOS MChief Executive Officer | Grant | 1.06M | — | — | Jun 16, 2026 |
| WASMAN JANEDirector | Grant | 50.0k | — | — | Jan 7, 2026 |
| CICIC DRAGANOfficer | Grant | 300.0k | — | — | Jan 7, 2026 |
| BURNS JOHN THOMASChief Financial Officer | Grant | 300.0k | — | — | Jan 7, 2026 |
| KALIN KATHERINE BACHDirector | Grant | 50.0k | — | — | Jan 7, 2026 |
| VARIAN JOHN WDirector | Grant | 50.0k | — | — | Jan 7, 2026 |
| VAN NOSTRAND ROBERT LDirector | Grant | 50.0k | — | — | Jan 7, 2026 |
| SCHEINBERG DAVID ADirector | Grant | 50.0k | — | — | Jan 7, 2026 |
| KALIN KATHERINE BACHDirector | Buy | 63.4k | $1.59 | $101k | Nov 19, 2025 |
| VAN NOSTRAND ROBERT LDirector | Buy | 10.0k | $1.48 | $15k | Jun 12, 2025 |
| WASMAN JANEDirector | Buy | 20.0k | $1.69 | $34k | May 30, 2025 |
| KALIN KATHERINE BACHDirector | Buy | 20.0k | $1.80 | $36k | May 22, 2025 |
| WASMAN JANEDirector | Grant | 12.5k | — | — | Jan 10, 2025 |
| CICIC DRAGANOfficer | Grant | 194.3k | — | — | Jan 10, 2025 |
| BURNS JOHN THOMASChief Financial Officer | Grant | 194.3k | — | — | Jan 10, 2025 |
| STERGIOU ANGELOS MChief Executive Officer | Grant | 500.9k | — | — | Jan 10, 2025 |
| KALIN KATHERINE BACHDirector | Grant | 12.5k | — | — | Jan 10, 2025 |
| VARIAN JOHN WDirector | Grant | 12.5k | — | — | Jan 10, 2025 |
| VAN NOSTRAND ROBERT LDirector | Grant | 12.5k | — | — | Jan 10, 2025 |
| SCHEINBERG DAVID ADirector | Grant | 12.5k | — | — | Jan 10, 2025 |
No analyst notes on SLS yet.
Analyst Ratings
2 analysts covering
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Consensus |
|---|---|---|---|---|---|---|
| Current | 1 | 1 | 0 | 0 | 0 | Buy1.50 |
| 1 mo ago | 1 | 1 | 0 | 0 | 0 | Buy1.50 |